摘要
目的分析乌司他丁与奥曲肽对重症急性胰腺炎血小板活化因子(PAF)、细胞间粘附分子-1(ICAM-1)、免疫功能水平影响及临床治疗效果。方法回顾性选取2012年1月-2017年12月我院收治的重症胰腺炎患者104例,根据治疗方法不同分为对照组和观察组。对照组患者采用奥曲肽治疗,观察组患者采用奥曲肽联合乌司他丁治疗,分析两组患者治疗后的临床效果。结果观察组患者腹痛消失时间、肠鸣音恢复时间和体温、尿淀粉酶、血淀粉酶恢复正常时间均短于对照组(P<0.05)。治疗前,两组患者IgA、IgM、IgG水平比较无统计学差异(P>0.05)。治疗后,观察组患者IgG水平高于对照组,但IgA、IgM水平与对照组比较无统计学差异(P>0.05)。治疗前,两组患者ET、HLA-DR、HSP70、PAF、ICAM-1水平比较无统计学差异(P>0.05)。治疗后,观察组患者HLA-DR水平高于对照组,ET、HSP70、PAF、ICAM-1水平低于对照组(P<0.05)。观察组患者不良反应率为5.77%,对照组为19.23%,观察组患者不良反应率低于对照组(P<0.05)。结论乌司他丁联合奥曲肽治疗重症急性胰腺炎可有效控制患者临床症状,改善患者免疫功能,降低患者血清中ET、PAF、ICAM-1的表达,且不良反应轻,安全性高。
Objective To analyze the effects of ulinastatin and octreotide on the levels of platelet activating factor(PAF),intercellular adhesion molecule-1( ICAM-1) and clinical efficacy in patients with severe pancreatitis.Methods One hundred and four cases of severe pancreatitis admitted between January 2012 and December 2017 were divided into the control group and the observation group according to the treatment method. The patients in the control group were treated with octreotide,while those in the observation group were treated with octreotide plus ulinastatin. The clinical effects of the two groups were compared.Results The time taken to kill abdominal pain,to resume bowel sound and to restore the normal body temperature,urine amylase and serum amylase was shorter in the observation group than in the control group(P<0.05). Before treatment,the levels of IgA,IgM and IgG showed no significant difference between the two groups(P>0.05). After treatment,the level of IgG in the observation group was higher than that of the control group,but there was no significant difference in the levels of IgA or IgM between the two groups(P>0.05). Before treatment,the levels of ET,HLA-DR,HSP70,PAF and ICAM-1 showed no significant difference between the two groups(P>0.05). After treatment,the levels of HLA-DR and ICAM-1 in the observation group were higher than those in the control group(P<0.05). The adverse reaction rate was 5.77% in the observation group,significantly lower than that in the control group(19.23%)(P<0.05).Conclusion Ulinastatin combined with octretin in the treatment of severe pancreatitis can effectively control the clinical symptoms of patients,improve their immune function,reduce the expressions of serum ET,PAF and ICAM-1,with mild adverse reactions.
引文
[1]肖锋,陈隆望,郑辛甜.重症急性胰腺炎[J].中华急诊医学杂志,2016,25(10):1348.
[2]周盛萍,周容.围生期重症急性胰腺炎的发病特点及诊治原则[J].实用妇产科杂志,2016,32(1):13.
[3]李静,黄路明,杨文娟,等.重症急性胰腺炎时的免疫反应对治疗策略的启示[J].中华消化杂志,2015,35(4):279.
[4]张东,潘伟云,丁黎莉,等.急性胃肠损伤分级诊治策略在重症急性胰腺炎患者营养支持中的应用[J].中华急诊医学杂志,2015,24(7):784.
[5]孙备,冀亮.创伤递升式分阶段治疗重症急性胰腺炎的临床实践与思考[J].中华外科杂志,2015,53(9):653.
[6]MAHESHWARI R,SUBRAMANIAN R M.Severe acute pancreatitis and necrotizing pancreatitis[J].Crit Care Clin,2016,32(2):279.
[7]ITALIAN ASSOCIATION FOR THE STUDY OF THE PAN-CREAS(AISP),PEZZILLI R,ZERBI A,et al.Consensus guidelines on severe acute pancreatitis[J].Dig Liver Dis,2015,47(7):532.
[8]唐虹.乌司他丁、血必净联合治疗对烧伤后脓毒症凝血功能及全身炎性反应影响的临床研究[J].中国医科大学学报,2015,44(12):1132.
[9]潘志国,邵玉,耿焱,等.乌司他丁对热打击血管内皮细胞增殖及炎症因子释放的影响[J].解放军医学杂志,2015,40(5):362.
[10]李群,朱平.乌司他丁治疗重型急性胰腺炎的疗效及其对患者血清炎症因子水平的影响[J].山东医药,2015,55(32):64.
[11]BAMBIRRA W J,MACIEL K F,THEBIT M M,et al.Assessment of apical expression of alpha-2 integrin,heat shock protein,and proinflammatory and immunoregulatory cytokines in response to endodontic infection[J].JEndod,2015,41(7):1085.
[12]KLINGSPOR S,BONDZIO A,MARTENS H,et al.Enterococcus faecium NCIMB 10415 modulates epithelial integrity,heat shock protein,and proinflammatory cytokine response in intestinal cells[J].Mediators Inflamm,2015,2015:304149.
[13]JACOB A O,STEWART P,JACOB O.Early surgical intervention in severe acute pancreatitis:Central Australian experience[J].ANZ J Surg,2016,86(10):805.
[14]PATEL K,TRIVEDI R N,DURGAMPUDI C,et al.Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation[J].Am JPathol,2015,185(3):808.
[15]郭华,陈炅,索冬卫.奥曲肽联合乌司他丁治疗急性重症胰腺炎临床疗效及安全性分析[J].中华医学杂志,2015,95(19):1471.
[16]MOGGIA E,KOTI R,BELGAUMKAR A P,et al.Pharmacological interventions for acute pancreatitis[J].Cochrane Database Syst Rev,2017,4:CD011384.
